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Background: 
New medical technologies are often used widely without adequate supporting data, a 
practice that can lead to widespread catastrophic failure such as occurred with metal-on-
metal (MoM) hip replacements. We determined both how revision rates would have differed 
if, instead of receiving MoM hip replacements, patients had received existing alternatives 
and the subsequent cumulative re-revision rates of the patients who did receive MoM hip 
replacements compared with alternatives. 
Methods: 
This study is a population-based longitudinal cohort study of patient data recorded in the 
National Joint Registry (NJR) for England, Wales and Northern Ireland between April 2003 
and December 2014. We ascertained implant failure rates separately among stemmed MoM 
total hip replacement (THR) and hip-resurfacing procedures and, using flexible parametric 
survival modeling, compared them with the failure rates that would have been expected had 
existing alternatives been used. We used Kaplan-Meier survivorship analysis to compare 
cumulative re-revision of patients who received stemmed MoM primary replacements that 
failed and of those who underwent hip resurfacing that failed with those whose non-MoM 
THRs had failed. 
Results: 
In all, 37,555 patients underwent MoM hip resurfacing, with a 10-year revision rate of 12.6% 
(95% confidence interval [CI]: 12.2% to 13.1%) compared with a predicted revision rate of 
4.8% if alternative implants had been used. The 32,024 stemmed MoM THRs had a 19.8% 
(95% CI: 18.9% to 20.8%) 10-year failure rate compared with an expected rate of 3.9% if 
alternatives had been used. For every 100 MoM hip-resurfacing procedures, there were 7.8 
excess revisions by 10 years, and for every 100 stemmed MoM THR procedures, there were 
15.9, which equates to 8,021 excess first revisions. Seven-year re-revision rates were 14.9% 
(95% CI: 13.8% to 16.2%) for stemmed non-MoM THRs, 18.0% (95% CI: 15.7% to 20.7%) 
for MoM hip resurfacing, and 19.8% (95% CI: 17.0% to 23.0%) for stemmed MoM THRs. 
Conclusions: 
This study highlights the consequences of widespread and poorly monitored adoption of a 
medical technology. Over 1 million MoM hip prostheses were implanted worldwide. The 
excess failure on a global scale will be enormous. This practice of adopting new 
technologies without adequate supporting data must not be repeated. 
Level of Evidence: 
Therapeutic Level III. See Instructions for Authors for a complete description of levels of 
evidence. 
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New technologies are constantly being introduced into medical practice. These 
technologies undergo extensive preclinical testing, but once in clinical use they are often not 
effectively evaluated. Initial published data are usually from inventors and manufacturers and 
therefore may not be generalizable. One prominent example is metal-on-metal total hip 
replacements (MoM THRs). Over 1 million of these devices were implanted worldwide 
before National Joint Registry (NJR) data from England and Wales first demonstrated 
unacceptably high failure rates1,2. These findings were also noted in Australia, Spain, Italy, 
the U.S., and Nordic countries3,4. 
Stemmed MoM THR and hip-resurfacing implants became popular between 2003 and 
2008 because surgeons believed that these would have lower failure rates than existing 
alternatives, particularly in younger patients, in whom wear and failure rates are higher with 
established types of hip replacement5. This belief was based on tribological laboratory 
observations that MoM bearings had very low wear rates6,7. In addition, lower wear rates 
would allow the use of larger femoral heads, which would decrease the risk of dislocation8. 
By 2008, approximately one-third of all hip replacements being performed in the U.S. and 
14% of all hip replacements being performed in England and Wales were MoM9. 
Randomized studies comparing MoM hip resurfacing with THR were underpowered to 
determine whether there were any significant differences between the interventions, and the 
results of these studies appeared late in the course of introducing the MoM technology10-12. 
Unfortunately, both MoM hip resurfacing1 and MoM stemmed THR2,13 went on to fail at 
much higher rates than the alternatives did. The usage of such implants subsequently declined 
to <1% of all hip replacements performed in England and Wales in 20149. However, the NJR 
has recorded nearly 70,000 MoM hip replacements implanted between April 2003 and 
December 20149. 
We believe that health-care systems worldwide were essentially involved in a large-
scale uncontrolled trial without understanding the long-term implications or the potential 
impact on failure rates of the joint prostheses implanted and on the patients who received 
them. The present analysis had 2 arms, stemmed MoM and resurfacing MoM prostheses. It is 
well documented elsewhere that the failure mechanisms and outcomes differ between these 2 
arms1,2, but neither stemmed MoM nor resurfacing MoM has been a clinical success. We 
wished to ascertain the consequences of using MoM hip prostheses by determining the excess 
revision rate attributable to MoM hip-resurfacing and MoM THR prostheses implanted 
during this period. We achieved this aim by modeling what the outcomes would have been in 
patients who received MoM hip replacements (assessing stemmed MoM and hip resurfacing 
separately) if the technology had never been introduced and instead patients had received the 
alternative technologies in use (non-MoM hip replacements) according to age, sex, and 
diagnosis leading to hip replacement. We compared this information with the actual 
outcomes that these patients experienced to determine the excess failure rates. Lastly, we 
determined the re-revision rate for hips that had been revised and we documented the reasons 
for revision of all first revision procedures. 
Materials and Methods 
The base dataset was 708,311 linked primary hip replacements performed in England 
and Wales between April 1, 2003, and December 31, 2014, and described in the 12th Annual 
Report of the NJR14. The Data Quality Audit suggests that in recent years approximately 3% 
of primary replacements and 5% of revisions were not recorded in the NJR15. In addition, 
annual implant sales in England and Wales have corresponded extremely well with the 
recorded number of arthroplasties performed. Approximately 10% of recorded procedures 
have been lost because of linkage issues, as no suitable person-level identifier could be found. 
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Around half of these losses are because patients declined to give consent for their data to be 
held. 
Implants were divided into 3 groups: stemmed THRs with MoM bearings (n = 
32,024), MoM hip-resurfacing protheses (n = 37,555), and all other stemmed THRs with 
other combinations of bearing surfaces (non-MoM; n = 626,314). The bearing-surface 
combination implanted could not be established in 11,977 cases because of missing 
information, and a further 441 cases were excluded because some ambiguity was found in the 
data recorded in the NJR. Table I illustrates that the proportions of stemmed MoM THRs and 
hip-resurfacing procedures rose to peaks at 2008 and 2006, respectively, and both 
subsequently fell. 
First, we sought to compare the outcomes of the stemmed MoM THRs and MoM hip-
resurfacing procedures with the stemmed THRs with non-MoM bearing surfaces and, for the 
stemmed MoM THRs and MoM hip-resurfacing procedures, to compare actual outcomes 
with outcomes expected had other bearing-surface combinations been used instead of the 
MoM bearing. The 12,418 implants with uncertain bearing surfaces (1.8%) were excluded, 
leaving 695,893 cases available for analysis. Second, we wished to ascertain whether the hips 
that were revised required re-revision. 
Statistical Methods 
The primary outcome of interest for this analysis was the time elapsed from the 
primary procedure to the first recorded linked revision procedure. We used survival methods 
to account for censoring, with either the date of December 31, 2014, or the date of death if 
the patient had died before then. The maximum potential follow-up available was 11.75 
years. 
We developed a prediction model from a 90% random sample of the stemmed non-
MoM set (the training set), retaining the remaining 10% for model validation (the test set). 
Predictors used in the model were sex, continuous age in years at the primary 
operation (as 4 restricted cubic splines), and the reason for the primary procedure 
(osteoarthritis [OA] only, other indication [with or without OA], and any trauma, with any 
trauma overriding all other indications). For the modeling, we used flexible parametric 
survival modeling16,17 as implemented in Stata (version 14; StataCorp)14, which 
accommodates time-varying effects of the predictor variables. The latter time-varying effects 
were assessed using likelihood ratio tests and examination of the Akaike and Bayesian 
information criteria (AIC and BIC, respectively). 
Proportional hazards regression models can be expressed on the natural logarithm of 
the cumulative hazards (ln{H} scale as ln{H(t/xi)} = ln{Ho(t)} + xiβ, where xi are covariates 
in the model and β is a vector of their coefficients (to be determined). In flexible parametric 
survival modeling, the logarithm of the baseline cumulative hazard (ln{Ho(t)}) is modeled as 
a restricted cubic spline function of the logarithmically transformed time from the primary 
procedure (ln{t}) as fully described by Lambert and Royston17 The methodology allows 
time-varying effects of the model covariates to be explored by forming interactions between 
them and the spline function for the baseline hazard; splines with fewer knots can be used for 
these effects than for the baseline17. 
The developed model was used to make out-of-sample cumulative revision 
predictions for the other 3 groups: the stemmed non-MoM THR test set (to validate the 
model), the stemmed MoM THR implants, and the MoM hip-resurfacing implants. For each 
of these groups, the actual cumulative revision estimates (Kaplan-Meier estimates) were 
compared with those predicted from the model. For the stemmed MoM THR and the MoM 
hip-resurfacing groups, the predicted cumulative revision would be the expected results had 
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the patients been managed in the same way as those who received the stemmed non-MoM 
implants, allowing for age, sex, and indication. 
Fixation was not included in the prediction model. The decision to use MoM implants 
would, by definition, have been constrained to uncemented or hybrid fixation. Had other 
bearing surfaces been used instead, it would not necessarily follow that they would have had 
the same method of fixation. Similarly, head size was not included in the prediction. First, all 
resurfacing protheses would have had large heads (diameter, ≥36 mm) by definition and, 
second, where a stemmed MoM THR was used with a large head, it would not follow that a 
large head would have been used if a different bearing-surface combination had been used. 
In the hips that were revised, we then used Kaplan-Meier survivorship analysis to 
estimate the cumulative re-revision by year from first revision. 
Results 
A summary of the variables for analysis, with comparisons among the various 
subgroups, is shown in Table II. The numbers with missing data were small and were 
similarly distributed in the subgroups. In total, there were no data available on the indication 
for the primary procedure for 61 implants, the age was missing (not validated because the 
National Health Service number was not traced) for 341 implants, and the patient sex was not 
available for 6 implants. 
Outcome in terms of time to revision is known to depend on the sex and age of the 
patient14. Among the stemmed non-MoM THRs, cumulative revision (Kaplan-Meier 
estimate) was progressively worse where there were “other indications” for the primary 
procedure or “any trauma” than when the indication was “OA [osteoarthritis] only” (see 
Appendix). However, these differences are seen in univariate analyses (see Appendix) and 
may reflect the interrelationships between these factors and the age and sex of the patient 
For prediction of outcome, we used age, sex, and risk group (reason for the primary 
procedure). A series of exploratory analyses on the stemmed non-MoM THR training set 
(data not shown; n = 563,354 cases with complete information) suggested that 3 knots (i.e., 4 
degrees of freedom) would give a satisfactory fit for the baseline hazard. Sex, age, and risk 
group all had time-varying effects, with respective degrees of freedom of 1, 2, and 2. Out-of-
sample prediction based on this model for the 3 groups (the stemmed non-MoM THR test set, 
the stemmed MoM THRs, and the MoM hip-resurfacing group) are plotted in Figure 1. This 
modeling shows the predicted outcomes if stemmed and resurfacing MoM implants had not 
been used in these specific patients. These predicted outcomes suggest that slightly worse 
cumulative revision results would be expected for MoM hip resurfacing and stemmed MoM 
THRs than for the stemmed non-MoM THRs, probably reflecting the fact that these groups 
were more heavily weighted to men and to younger patients. In Figure 2, the actual 
cumulative revision rates (Kaplan-Meier) with pointwise 95% confidence intervals (CIs) have 
been added. For stemmed MoM THRs and MoM hip resurfacing, the actual results were 
much worse than expected a priori, with stemmed MoM THRs showing a more marked 
difference. These rates contrasted with those for the stemmed non-MoM THR test set, in 
which the cumulative revision rates were close to their expected values, validating the model. 
Table III documents the actual cumulative revision rates for the stemmed non-MoM 
THR test set, the stemmed MoM THRs, and the MoM hip-resurfacing group compared with 
their expected cumulative revision rates estimated from the model. It can be seen that, for 
every 100 stemmed MoM THR implants, there were 15.9 (19.8 − 3.9) excess revisions by 10 
years. Similarly, for every 100 MoM hip-resurfacing procedures, there were 7.8 (12.6 − 4.8) 
excess revisions by 10 years. Finally, Figure 3 (as well the Appendix) shows the re-revision 
rates of the hips that were revised during the study period. Seven-year re-revision rates were 
14.9% (95% CI: 13.8% to 16.2%) for stemmed non-MoM THRs, 18.0% (95% CI: 15.7% to 
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20.7%) for MoM hip resurfacing, and 19.8% (95% CI: 17.0% to 23.0%) for stemmed MoM 
THRs. 
“Adverse reaction to metal debris” as an option for the reason for revision was not 
added to the minimum data set of the NJR until 2008. Thirty-three percent of resurfacing 
revisions and 46% of stemmed MoM revisions were performed for adverse reaction to metal 
debris from 2008 until December 2014, compared with only 2% of the revisions performed 
on non-MoM THRs. The reasons for revision are outlined in the Appendix. 
Discussion 
Our model predicts that every 100 MoM hip-resurfacing procedures performed would 
result in 7.8 additional revision hip replacements within 10 years and every 100 stemmed 
MoM THRs, in 15.9 additional revision hip replacements within 10 years. In all, 32,024 
stemmed MoM THRs and 37,555 MoM hip-resurfacing prostheses were implanted between 
April 2003 and December 2014, resulting in a prediction of 8,021 excess first revisions 
within 10 years of implantation. Data capture in the early years of the NJR was incomplete 
and, thus, our numbers are an underestimation of this problem. MoM hip replacement 
protheses are still being implanted worldwide in 2017. In all, 790 resurfacing and 67 
stemmed MoM THR procedures were recorded in the NJR in 2014 even though the 
unacceptably high failure rates for these devices were published in The Lancet in 20121,2. 
Furthermore, of the MoM hip replacements that have been revised (either to non-
MoM or MoM prostheses) in England and Wales, nearly 1 in 5 required re-revision within 7 
years. This rate is greater than that for stemmed non-MoM THRs, and the difference becomes 
more marked with time. Many surgeons were attracted to resurfacing as revision of the 
femoral component is much easier than revision of a stemmed femoral component because 
the integrity of the femoral metaphysis and diaphysis is preserved. However, the data 
presented show that these so-called easier revisions lead to higher re-revision rates, most 
likely explained by the fact that there were different reasons for first revision between the 
groups as well as the fact that, in some first revisions following resurfacing procedures, an 
MoM articulation was maintained when only 1 component was revised. 
The personal and societal costs of revision hip surgery are enormous. Both the failure 
of the implant and the subsequent revision cause the patient pain, loss of function, and loss of 
participation in society. The hospital costs of each revision episode are approximately 
$16,800 (£12,000)19. In total, 8,021 excess first revisions over 10 years will thus cost the 
National Health Service in England and Wales approximately $140 million (£100 million). 
Furthermore, there are the additional costs of second and subsequent revisions and follow-up 
appointments, including blood tests for cobalt and chromium levels, magnetic resonance 
imaging (MRI), and ultrasound (as recommended by the Medicines & Healthcare products 
Regulatory Agency for MoM hip replacements) and the cost of treating disability and pain as 
well as lost employment. 
MoM hip prostheses have been used extensively worldwide. It is estimated that over 1 
million have been implanted20 and, at their peak, they accounted for approximately one-third 
of the hip replacements performed in the U.S.21. Our patients are similar in age, diagnosis, 
body mass index, and sex to those in most registries, and the implants used are manufactured 
by the same companies. Our results are thus likely to be generalizable to other health-care 
settings outside of the U.K. Simply comparing failure rates between patients who underwent 
MoM THRs and those who did not would not be valid, as the groups vary considerably 
according to age and sex, factors that are on the causal pathway of hip failure. It is well 
established that failure rates after stemmed MoM replacement procedures are proportional to 
prosthetic head size1 and, after resurfacing MoM, inversely proportional to head size2. If the 
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MoM procedures had been confined to only small-diameter stemmed articulations and large-
diameter resurfacing, then the results would have been better. 
Our model appears to be valid as it accurately predicted the actual failure in the test 
set of non-MoM hip replacements and thus the predictions for the 2 MoM groups are likely to 
be correct. Furthermore, the modeling is particularly pertinent as it allows us to compare the 
outcomes with the outcomes most likely had the patients received the same prostheses as 
those who did not receive MoM implants but who were of the same age and sex and had the 
same diagnosis and were treated in the same health-care setting contemporaneously. If the 
same analysis were to be performed in another health-care setting, such as the U.S., then the 
outcome of the modeling would be slightly different because of differences in practice, such 
as greater usage of uncemented implants. 
A major strength of this analysis is the large cohorts involved, allowing us to 
determine associations between the choice of implant at the time of the primary procedure 
and the subsequent risk of revision surgery and also allowing us to construct a robust model 
using patient age, sex, and diagnostic reason for the hip replacement to predict the outcome 
had MoM options not been available. Although data-capture rates in the NJR are very high, 
in the early years of the registry, data capture was not complete. We have no reason to 
believe that this incomplete data capture would have differed between the different types of 
hip replacement, and therefore these data can be considered to be missing at random and to 
not affect the results observed. Inherent in the establishment of any registry is the fact that 
capture will initially be incomplete until the registry is fully established. This issue is 
mitigated by the fact that we are looking at time to revision from primary procedures 
recorded in the registry. Therefore, any revisions not recorded in the early years are most 
likely to be of primary operations that were performed prior to the establishment of the 
registry and thus have no bearing on this analysis. The 13th Annual Report shows that only 
3% of the revisions recorded in 2003 were of primary procedures recorded in the NJR, rising 
to 41% in 20159. 
It is important to note that the 6th Annual Report, published in 2009, clearly showed 
much higher failure rates with MoM resurfacing with only 3 years of follow-up, which may 
have contributed to the rapid decline in usage of these implants in England and Wales after 
200922. 
In conclusion, this study highlights the consequences of the rapid and widespread 
introduction of medical technology without adequate knowledge or understanding of the 
potential long-term outcomes. It was not necessary to implant over 1 million of these devices 
before the outcomes were ascertained. The post-market surveillance requirements of the 
regulators were insufficiently stringent to ensure early detection of potentially adverse 
outcomes. We have used the example of MoM hip replacements, but the principle of effective 
regulation and post-market surveillance applies to devices in all branches of medicine. We 
are hopeful that lessons will be learned to guide the introduction of implants and devices into 
clinical practice in the future. 
Appendix 
Tables showing the relationship between patient sex, age, and reason for the primary 
operation; the relationship between sex, age, and fixation in patients with stemmed non-MoM 
THR implants; the numbers of first revisions and re-revisions, by implant type; the risk of re-
revision, by time since first revision; reasons for the first revision, by implant type; and the 
main reasons for revision, by time since the primary operation; and a figure showing the 
cumulative percentage probability of revision for stemmed non-MoM THR implants, by 
indication for the primary operation, are available with the online version of this article as a 
data supplement at jbjs.org. 
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Fig. 1 
Graph showing the model-predicted cumulative percentage probability of revision. Out-of-
sample prediction was made using the model developed from the training set, with age, sex, 
and reason for the primary procedure (risk group) as the predictors. There were 563,354 
cases with complete information in the training set; the respective prediction-group sizes 
were 62,589 cases in the stemmed non-MoM THR test set (black dashed line), 32,009 cases 
in the stemmed MoM THR group (red dashed line), and 37,533 cases in the MoM hip-
resurfacing group (blue dashed line). 
Fig. 2 
Graph showing the model-predicted cumulative percentage probability of revision compared 
with the actual cumulative percentage revision. The model-predicted cumulative percentage 
probability of revision for the stemmed non-MoM THR test set is shown with the black 
dashed line; for the stemmed MoM THR group, with the red dashed line; and for the MoM 
hip-resurfacing group, with the blue dashed line. The actual cumulative percentage revision 
is shown with solid lines (Kaplan-Meier with 95% CI [shading]). 
Fig. 3 
Graph showing the cumulative percentage probability of re-revision, grouped by type of 
primary hip replacement: stemmed non-MoM THR test set (black line), stemmed MoM THR 
group (red line), and MoM hip-resurfacing group (blue line). The respective numbers at risk 
for re-revision for these 3 groups at 0, 2, 4, 6, and 8 years after the first revision are shown 
below the graph. 
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TABLE I Number of Primary Hip Replacements, by Type of Implant, in Each Year of the Registry 
Year of 
Primary Op. 
Stemmed THR Implants* 
MoM 
Resurfacing* 
Implants with Uncertain/Ambiguous 
Bearing Surfaces* Total MoM 
All Other Bearing 
Surfaces 
2003 (from 
April 1) 
303 (2.1%) 12,192 (84.5%) 1,415 (9.8%) 514 (3.6%) 14,424 
2004 861 (3.1%) 23,558 (84.1%) 2,860 (10.2%) 734 (2.6%) 28,013 
2005 2,525 
(6.3%) 
32,343 (80.5%) 4,262 (10.6%) 1,051 (2.6%) 40,181 
2006 4,518 
(9.5%) 
36,758 (77.3%) 5,121 (10.8%) 1,153 (2.4%) 47,550 
2007 6,977 
(11.5%) 
45,892 (75.8%) 6,217 (10.3%) 1,436 (2.4%) 60,522 
2008 8,084 
(12.1%) 
51,305 (76.7%) 5,953 (8.9%) 1,508 (2.3%) 66,850 
2009 5,726 
(8.4%) 
56,345 (83.1%) 4,439 (6.5%) 1,294 (1.9%) 67,804 
2010 2,406 
(3.4%) 
63,624 (90.6%) 2,725 (3.9%) 1,458 (2.1%) 70,213 
2011 395 (0.5%) 69,428 (94.8%) 1,846 (2.5%) 1,551 (2.1%) 73,220 
2012 118 (0.2%) 75,535 (97.7%) 1,066 (1.4%) 602 (0.8%) 77,321 
2013 44 (0.1%) 77,595 (98.1%) 861 (1.1%) 588 (0.7%) 79,088 
2014 67 (0.1%) 81,739 (98.3%) 790 (1.0%) 529 (0.6%) 83,125 
Total 32,024 
(4.5%) 
626,314 
(88.4%) 
37,555 (5.3%) 12,418 (1.8%) 708,311 
*The values are given as the number of implants, with the percentage in parentheses. 
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TABLE II Comparison of Variables of Interest for Analysis Across Groups 
  Stemmed MoM 
THR 
MoM Hip 
Resurfacing 
Stemmed Non-MoM THR 
All Cases 90% Training Set 10% Test Set 
No. of cases 32,024 37,555 626,314 563,683 62,631 
Males* 16,114 
(50.3%) 
26,413 
(70.3%) 
237,916 
(38.0%) 
214,262 
(38.0%) 
23,654 (37.8%) 
Median age at 
primary op. (IQR)† 
(yr) 
64 (57 to 71) 55 (49 to 60) 70 (63 to 77) 70 (63 to 77) 70 (63 to 77) 
Indication for 
primary op. 
          
OA only* 28,174 
(88.0%) 
34,169 
(91.0%) 
561,390 
(89.6%) 
505,390 
(89.7%) 
56,000 (89.4%) 
Other indication* 2,762 (8.6%) 3,051 (8.1%) 40,861 (6.5%) 36,704 (6.5%) 4,157 (6.6%) 
Any trauma* 1,084 (3.4%) 330 (0.9%) 24,011 (3.8%) 21,541 (3.8%) 2,470 (3.9%) 
No. of cases with 
missing 
indication‡ 
4 5 52 48 4 
*The values are given as the number, with the percentage in parentheses. †IQR = interquartile range. ‡For 61 implants, no 
data were available on the indication for the primary operation. 
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TABLE III Comparison Between Actual Cumulative Percentage Probability of Revision and the Model-Estimated 
Cumulative Percentage Probability of Revision Had Patients Not Received MoM Prostheses 
 Cumulative Percentage Probability of Revision* 
Stemmed Non-MoM THR, 
Test Set Stemmed MoM THR MoM Hip Resurfacing 
Actual Estimated Actual Estimated Actual Estimated 
Time since 
primary 
op. 
      
1 yr 0.64 (0.58-
0.71) 
0.7 1.0 (0.9-1.1) 0.8 1.3 (1.1-1.4) 0.8 
3 yr 1.3 (1.2-1.4) 1.4 3.3 (3.1-3.5) 1.5 3.1 (2.9-3.3) 1.7 
5 yr 1.8 (1.7-1.9) 2.0 7.4 (7.2-7.8) 2.2 5.7 (5.4-5.9) 2.6 
7 yr 2.4 (2.2-2.6) 2.5 12.7 (12.3-
13.1) 
2.9 8.7 (8.4-9.0) 3.5 
10 yr 3.5 (3.2-3.9) 3.3 19.8 (18.9-
20.8) 
3.9 12.6 (12.2-
13.1) 
4.8 
*The values are given as the actual cumulative percentage probability of revision (Kaplan-Meier), with the 95% CI in 
parentheses, and as the model-estimated cumulative percentage probability of revision (interpolated flexible parametric 
survival modeling estimates) had patients not received MoM prostheses, by time since the primary operation. 
